Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-quinolinecarboxylic Acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-1,4-dihydro-4-oxo-
2. Xtoro
1. 209342-40-5
2. Xtoro
3. Finafloxacin [inn]
4. D26osn9q4r
5. Al-60371
6. Chebi:85176
7. Finafloxacin (inn)
8. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
9. Bay35-3377
10. (-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
11. 7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic Acid
12. Gastrochinolon
13. Gastroquinolone
14. 8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid
15. Xtoro (tn)
16. Finafloxacin [mi]
17. Unii-d26osn9q4r
18. Finafloxacin [who-dd]
19. Schembl1002869
20. Chembl1908370
21. Gtpl10809
22. Dtxsid10175096
23. Finafloxacin [orange Book]
24. Bcp23882
25. Zinc3985346
26. Al60371
27. Cs-5557
28. Db09047
29. Ncgc00510315-02
30. (-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1
31. Ac-29291
32. Hy-13451
33. D10575
34. Q21011229
35. 3-quinolinecarboxylic Acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2h)-yl]-1,4-dihydro-4-oxo-
36. 7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic Acid,hydrochloride
37. 8-cyano-1-cyclopropyl-6-fluoro-7-((1s,6s)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid
38. 8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid
Molecular Weight | 398.4 g/mol |
---|---|
Molecular Formula | C20H19FN4O4 |
XLogP3 | -0.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 3 |
Exact Mass | 398.13903326 g/mol |
Monoisotopic Mass | 398.13903326 g/mol |
Topological Polar Surface Area | 106 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 806 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.
FDA Label
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Anti-Infective Agents, Urinary
Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)
Topoisomerase II Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)
Finafloxacin is a fluoroquinolone antibiotic, which selectively inhibit bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination.
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Finafloxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Finafloxacin, including repackagers and relabelers. The FDA regulates Finafloxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Finafloxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Finafloxacin supplier is an individual or a company that provides Finafloxacin active pharmaceutical ingredient (API) or Finafloxacin finished formulations upon request. The Finafloxacin suppliers may include Finafloxacin API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Finafloxacin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Finafloxacin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Finafloxacin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Finafloxacin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Finafloxacin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Finafloxacin suppliers with NDC on PharmaCompass.
Finafloxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Finafloxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Finafloxacin GMP manufacturer or Finafloxacin GMP API supplier for your needs.
A Finafloxacin CoA (Certificate of Analysis) is a formal document that attests to Finafloxacin's compliance with Finafloxacin specifications and serves as a tool for batch-level quality control.
Finafloxacin CoA mostly includes findings from lab analyses of a specific batch. For each Finafloxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Finafloxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Finafloxacin EP), Finafloxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Finafloxacin USP).
LOOKING FOR A SUPPLIER?